Division of Infectious Diseases, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599, USA.
Sex Transm Dis. 2010 Mar;37(3):169-72. doi: 10.1097/OLQ.0b013e3181bf575c.
Malawi adopted syndromic management of sexually transmitted infections in 1993. Based on clinical efficacy and cost, gentamicin 240 mg intramuscularly, and doxycycline 100 mg twice daily x 7 days was selected as the first line regimen to treat urethritis. We sought to establish current laboratory-based Neisseria gonorrhoeae antibiotic susceptibility patterns for Malawi and describe the pattern of susceptibility since syndromic management began.
Between May 15 and August 10, 2007, 126 men with urethritis attending the STD clinic at Kamuzu Central Hospital in Lilongwe had history, genital exam, and urethral swabs taken. All were treated with gentamicin and doxycycline in accordance with Malawi guidelines. Gonorrhea was diagnosed by Gram stain and culture. Antimicrobial susceptibility patterns in gonococcal isolates were determined by disk diffusion and E-test minimum inhibitory concentration (MIC) determination and agar dilution MIC determination.
One hundred six isolates were cultured, and MICs were determined for 100. High levels of resistance to tetracycline and penicillin were observed, but isolates were uniformly susceptible to both gentamicin and ciprofloxacin. Susceptibility patterns identified by the agar dilution MIC and E-test MIC agreed.
The most recent study continues the trend of high susceptibility of gonococcal isolates to gentamicin in Malawi after 14 years of use and suggests agar dilution MICs may be substituted with the simpler E-test methods in future susceptibility testing. However because of the lack of susceptibility criteria for aminoglycosides for N. gonorrhoeae and the difficulty obtaining clinical/in vitro correlates in this setting, caution should be exercised in using these data for modifying treatment regimens.
马拉维于 1993 年采用性传播感染综合征管理。基于临床疗效和成本,选择庆大霉素 240mg 肌内注射和多西环素 100mg 每日两次 x7 天作为治疗尿道炎的一线方案。我们试图确定马拉维目前基于实验室的淋病奈瑟菌抗生素药敏模式,并描述自综合征管理开始以来的药敏模式。
2007 年 5 月 15 日至 8 月 10 日,126 名患有尿道炎的男性在利隆圭的卡姆祖中央医院性病诊所就诊,进行了病史、生殖器检查和尿道拭子采集。所有患者均按照马拉维指南用庆大霉素和多西环素治疗。淋病通过革兰氏染色和培养诊断。通过纸片扩散和 E 试验最低抑菌浓度(MIC)测定和琼脂稀释 MIC 测定来确定淋病奈瑟菌分离株的抗生素药敏模式。
培养了 106 株分离株,并确定了 100 株的 MIC。观察到对四环素和青霉素的高水平耐药,但分离株对庆大霉素和环丙沙星均具有均匀的敏感性。琼脂稀释 MIC 和 E 试验 MIC 确定的药敏模式一致。
在 14 年的使用后,最近的这项研究延续了马拉维淋球菌分离株对庆大霉素高度敏感的趋势,并表明琼脂稀释 MIC 方法可以在未来的药敏试验中替代更简单的 E 试验方法。然而,由于缺乏淋病奈瑟菌氨基糖苷类药物的药敏标准以及在这种情况下获得临床/体外相关性的困难,在修改治疗方案时应谨慎使用这些数据。